By : Business Editor
Jordan Daily – Jordanian Pharmaceutical Manufacturing Co (JPM) reported a strong rise in annual profit for 2025, posting preliminary net earnings of JOD 4.09 million, up about 538% from JOD 641,000 a year earlier.
Revenue climbed to JOD 23.56 million in 2025 from JOD 16.86 million in 2024, an increase of nearly 40%, the company said in a statement seen by Jordan Daily. Gross profit rose to JOD 12.11 million compared with JOD 7.72 million the previous year, reflecting improved operating margins and tighter cost management.
Chairman Abdul Jabbar Al-Kubaisi said the results marked a pivotal stage in the company’s growth trajectory, building on its return to profitability in 2024 and accelerating earnings momentum in 2025. He attributed the performance to higher sales, operational efficiencies and a strategic focus on expanding production capacity.
Chief Executive Abdulhamid Sinokrot said the preliminary 2025 results, equivalent to roughly $6 million in net profit, underscored the strength of the company’s strategy and execution, adding that JPM would continue to drive sustainable growth and reinforce Jordan’s pharmaceutical industry leadership.
The company said it upgraded production lines and introduced new technologies to boost capacity, improve quality and reduce costs, while expanding its presence in regional and international markets.